GlassScriptPhysician profile
Noopur Narula
NPI 1013302652
$4,619.02
in general payments reported to CMS, 2019-2025
18 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $246 · 2023: $706 · 2024: $1,379 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,373.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,512.06 | 2022-2025 | Descovy, Yeztugo, Epclusa |
| Viiv Healthcare Company | $471.69 | 2022-2025 | Apretude, Dovato |
| Novo Nordisk INC | $378.17 | 2023-2025 | Wegovy |
| Abbvie INC. | $254.15 | 2024-2025 | |
| Glaxosmithkline, LLC. | $243.05 | 2024-2025 | Arexvy |
| Braeburn INC. | $228.97 | 2024-2025 | Brixadi |
| Biogen, INC. | $207.84 | 2025 | Zurzuvae, Skyclarys, Tysabri |
| Madrigal Pharmaceuticals | $144.13 | 2024 | Rezdiffra |
| Abiomed | $137.41 | 2025 | |
| Xeris Pharmaceuticals, INC. | $124.99 | 2025 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $123.86 | 2024 | Nuzyra |
| Amgen INC. | $121.90 | 2025 | |
| Vanda Pharmaceuticals INC. | $120.47 | 2025 | Fanapt |
| Emd Serono, INC. | $120.40 | 2024 | Serostim |
| Lilly USA, LLC | $120.39 | 2023 | Mounjaro |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $119.77 | 2025 | Auvelity |
| Dexcom, INC. | $112.85 | 2024-2025 | Dexcom G6 Transmitter |
| Stryker Corporation | $76.92 | 2025 | Lifepak 15 Monitor/Defibrillator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noopur Narula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.